HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 48, 2009, Pages 20382-20387

  Dai, Bingbing ^a   Yang, Lili ^b   Yang, Haiguang ^a   Hu, Biliang ^a   Baltimore, David ^b   Wang, Pin ^a  

^a University of Southern California ^*  (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

AIDS vaccine; Human immunodeficiency virus; Lentiviral vector; T cell vaccine

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LENTIVIRUS VECTOR; LENTIVIRUS VECTOR GAG PROTEIN VACCINE; PRIMER DNA; RECOMBINANT ADENOVIRUS VECTOR 5 GAG PROTEIN VACCINE; TETRAMER; UNCLASSIFIED DRUG;

ARTICLE; BIOENGINEERING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOTYPING; SINDBIS VIRUS; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LENTIVIRUS; MICE; MICE, INBRED BALB C; SINDBIS VIRUS; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; SINDBIS VIRUS;

EID: 73949111672     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0911742106     Document Type: Article

References (47)

1. Barouch DH, Nabel GJ (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16:149-156.
2. Lasaro MO, Ertl HC (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17:1333-1339.
3. Buchbinder SP, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
4. McElrath MJ, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372:1894-1905.
5. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455:613-619.
6. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320:760-764.
7. Casimiro DR, et al. (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79:15547-15555.
8. Liu J, et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
9. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252.
10. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419-426.
11. Guermonprez P, et al. (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621-667.
12. Dorrell L (2005) Therapeutic immunization strategies for the control of HIV-1. Expert Rev Vaccines 4:513-520.
13. Rinaldo CR (2009) Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med 265:138-158.
14. Lapenta C, et al. (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198:361-367.
15. Yoshida A, et al. (2003) Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: Possible involvement of a novel factor of human CD4(+) T-cell origin. J Virol 77:8719-8728.
16. Lu W, et al. (2003) Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9:27-32.
17. Lu W, Arraes LC, Ferreira WT, Andrieu JM (2004) Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10:1359-1365.
18. Garcia F, et al. (2005) Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 191:1680-1685.
19. Tacken PJ, Torensma R, Figdor CG (2006) Targeting antigens to dendritic cells in vivo. Immunobiology 211:599-608.
20. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790-802.
21. Trumpfheller C, et al. (2006) Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 203:607-617.
22. Trumpfheller C, et al. (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105:2574-2579.
23. Yang L, et al. (2008) Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 26:326-334.
24. Dullaers M, Thielemans K (2006) From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 8:3-17.
25. VandenDriessche T, et al. (2002) Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100:813-822.
26. Esslinger C, et al. (2003) In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111:1673-1681.
27. Palmowski MJ, et al. (2004) Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 172:1582-1587.
28. Kim JH, et al. (2005) Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther 16:1255-1266.
29. Iglesias MC, et al. (2007) Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 15:1203-1210.
30. Lopes L, et al. (2008) Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 82:86-95.
31. Geijtenbeek TB, et al. (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575-585.
32. Caminschi I, et al. (2006) Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN. Int Immunol 18:741-753.
33. Tacken PJ, et al. (2005) Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106:1278-1285.
34. Lois C, et al. (2002) Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295:868-872.
35. Darrah PA, et al. (2007) Multifunctional TH1 cells define a correlate of vaccinemediated protection against Leishmania major. Nat Med 13:843-850.
36. Gavioli R, et al. (2008) The Tat protein broadens T cell responses directed to the HIV-1 antigensGagand Env: Implications for the design ofnewvaccination strategies against AIDS. Vaccine 26:727-737.
37. Tatsis N, et al. (2007) Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: Implications for their use as vaccines. Blood 110:1916-1923.
38. Wu L, Kong WP, Nabel GJ (2005) Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79:8024-8031.
39. Cox KS, et al. (2008) DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 82:8161-8171.
40. Kaufmann DE, et al. (2004) Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 78:4463-4477.
41. Gattinoni L, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616-1626.
42. Sun Y, et al. (2006) Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 80:10950-10956.
43. Yamamoto T, et al. (2009) Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection. J Virol 83:5514-5524.
44. Letvin NL, et al. (2006) Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533.
45. Janssen EM, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-856.
46. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339.
47. Kong WP, et al. (2003) Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77:12764-12772.